- Home
- NRXP vs DYAI Comparison
NRXP vs DYAI Comparison
Compare NRXP & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- DYAI
- Stock Information
- Founded
- NRXP 2015
- DYAI 1979
- Country
- NRXP United States
- DYAI United States
- Employees
- NRXP N/A
- DYAI N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRXP Health Care
- DYAI Health Care
- Exchange
- NRXP Nasdaq
- DYAI Nasdaq
- Market Cap
- NRXP 32.6M
- DYAI 28.3M
- IPO Year
- NRXP N/A
- DYAI 2004
- Fundamental
- Price
- NRXP $3.24
- DYAI $0.98
- Analyst Decision
- NRXP Strong Buy
- DYAI Strong Buy
- Analyst Count
- NRXP 4
- DYAI 1
- Target Price
- NRXP $28.50
- DYAI $6.00
- AVG Volume (30 Days)
- NRXP 204.8K
- DYAI 63.9K
- Earning Date
- NRXP 08-13-2025
- DYAI 08-12-2025
- Dividend Yield
- NRXP N/A
- DYAI N/A
- EPS Growth
- NRXP N/A
- DYAI N/A
- EPS
- NRXP N/A
- DYAI N/A
- Revenue
- NRXP N/A
- DYAI $3,554,344.00
- Revenue This Year
- NRXP N/A
- DYAI $22.56
- Revenue Next Year
- NRXP N/A
- DYAI $30.95
- P/E Ratio
- NRXP N/A
- DYAI N/A
- Revenue Growth
- NRXP N/A
- DYAI 57.59
- 52 Week Low
- NRXP $1.10
- DYAI $0.91
- 52 Week High
- NRXP $6.01
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- NRXP 53.62
- DYAI 53.08
- Support Level
- NRXP $2.90
- DYAI $0.91
- Resistance Level
- NRXP $3.53
- DYAI $0.99
- Average True Range (ATR)
- NRXP 0.20
- DYAI 0.06
- MACD
- NRXP -0.04
- DYAI 0.01
- Stochastic Oscillator
- NRXP 58.73
- DYAI 59.93
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.